We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.

Delisted

BHVN was delisted on the 3rd of October, 2022.

226 hedge funds and large institutions have $4.34B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2020 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 77 increasing their positions, 63 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

347% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 15

325% more call options, than puts

Call options by funds: $160M | Put options by funds: $37.7M

122% more capital invested

Capital invested by funds: $1.95B → $4.34B (+$2.39B)

60% more funds holding in top 10

Funds holding in top 10: 1016 (+6)

29% more funds holding

Funds holding: 175226 (+51)

22% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 63

Holders
226
Holders Change
+51
Holders Change %
+29.14%
% of All Funds
4.63%
Holding in Top 10
16
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+60%
% of All Funds
0.33%
New
67
Increased
77
Reduced
63
Closed
15
Calls
$160M
Puts
$37.7M
Net Calls
+$122M
Net Calls Change
+$22M
Name Holding Trade Value Shares
Change
Change in
Stake
MOACM
101
Mutual of America Capital Management
New York
$3.8M +$350K +6,576 +14%
First Trust Advisors
102
First Trust Advisors
Illinois
$3.79M +$2.76M +51,845 New
N
103
Natixis
France
$3.64M +$2.65M +49,789 New
Schroder Investment Management Group
104
Schroder Investment Management Group
United Kingdom
$3.46M +$1.24M +23,248 +97%
EIM
105
Essex Investment Management
Massachusetts
$3.39M -$1.17M -21,934 -32%
Fiera Capital (Canada)
106
Fiera Capital (Canada)
Quebec, Canada
$3.33M -$90.9K -1,708 -4%
GAI
107
General American Investors
New York
$3.29M -$1.06M -20,000 -31%
UBS AM
108
UBS AM
Illinois
$3.27M -$343K -6,445 -13%
IBT
109
International Biotechnology Trust
United Kingdom
$3.12M +$2.39M +45,000 New
HI
110
Handelsinvest Investeringsforvaltning
Denmark
$2.92M
State of New Jersey Common Pension Fund D
111
State of New Jersey Common Pension Fund D
New Jersey
$2.87M -$319K -5,993 -13%
Citigroup
112
Citigroup
New York
$2.58M -$127K -2,390 -6%
TCM
113
Tekla Capital Management
Massachusetts
$2.51M -$579K -10,887 -24%
BCM
114
Bluefin Capital Management
New York
$2.34M +$1.14M +21,475 +205%
Barclays
115
Barclays
United Kingdom
$2.28M -$8.95M -168,260 -84%
Legal & General Group
116
Legal & General Group
United Kingdom
$2.23M +$197K +3,700 +14%
EI
117
EAM Investors
California
$2.15M +$1.56M +29,385 New
PPA
118
Parametric Portfolio Associates
Washington
$2.13M +$760K +14,287 +96%
Man Group
119
Man Group
United Kingdom
$2.11M +$1.54M +28,884 New
AIG
120
American International Group
New York
$2.11M +$188K +3,529 +14%
LCS
121
Levin Capital Strategies
New York
$2.07M -$442K -8,310 -23%
Manulife (Manufacturers Life Insurance)
122
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.87M +$90.5K +1,700 +7%
T. Rowe Price Associates
123
T. Rowe Price Associates
Maryland
$1.86M -$38.7K -728 -3%
Asset Management One
124
Asset Management One
Japan
$1.84M
Principal Financial Group
125
Principal Financial Group
Iowa
$1.83M +$907K +17,036 +211%

BHVN Hedge Fund Activity: Q2 2020 in Review

226 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q2 2020, worth a combined $4.34B — up 122% from $1.95B a quarter earlier.

Buyers outnumbered sellers: 67 funds opened new BHVN positions and 15 closed out — a net gain of 52 holders — while 77 added to existing stakes and 63 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $52.2M. The largest seller was Wellington Management Group, cutting an estimated $55.1M.

  • 226 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q2 2020, up from 175 in Q1 2020.
  • Funds reported $4.34B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q2 2020, up 122% quarter-over-quarter.
  • 67 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q2 2020 and 15 closed out, a net change of +52 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q2 2020 was Tang Capital Management, an estimated $52.2M added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q2 2020 was Wellington Management Group, an estimated $55.1M sold.

Based on aggregated 13F filings for Q2 2020.